Stage 1: Longitudinal History & Clinical Course (Timestamp: 4-6 Years Prior to Admission)
A 72-year-old retired male executive residing in Delhi NCR (history of Type 2 Diabetes and Hypertension) presents to a tertiary care hospital with persistent high fevers, painful pustular skin lesions, macrocytic anemia, and refractory systemic inflammation.
Longitudinal History:
- 4-6 Years Ago: Developed symmetrical stiffness and joint pain in wrists, PIP joints, knees, and ankles. Evaluated at a rheumatology clinic; RF weakly positive, Anti-CCP negative. Diagnosed with seronegative RA and treated with Prednisolone, Methotrexate, Etanercept, and Adalimumab without durable response. Marked corticosteroid dependence developed (severe inflammatory flares whenever Prednisolone was tapered below 10 mg/day).
- 2 Years Ago: Developed painful violaceous plaques and urticarial neutrophilic dermatosis across the abdomen, chest, and thighs. Biopsy suggested a Sweet-like neutrophilic infiltrate.
- 9 Months Ago: Developed sudden right-sided sensorineural hearing loss (normal MRI brain), unexplainable persistent high fevers (38.5–39°C), weight loss, and tender subcutaneous nodules on the forearms.
- 3 Months Ago: Developed relapsing chondritis (ear/nose swelling), acute right foot drop (mononeuritis multiplex), a lower extremity DVT, and an episode of sterile vasoplegic inflammatory shock requiring ICU vasopressor support.
Hello, Chief Resident here.
Key Findings:
An older male with DMARD-refractory, steroid-dependent inflammatory arthritis, Sweet-like neutrophilic dermatosis, relapsing polychondritis, mononeuritis multiplex, sensorineural hearing loss, macrocytic anemia, DVT, and sterile vasoplegic shock.
Differential Diagnoses:
1. VEXAS Syndrome (65%): Classic presentation of this X-linked somatic autoinflammatory condition unifying macrocytic anemia, chondritis, neutrophilic dermatosis, vasculitis, thrombosis, and corticosteroid dependence in an older male.
2. Relapsing Polychondritis (15%): Explains auricular/nasal chondritis, hearing loss, and skin involvement, but often represents a phenotypic manifestation of underlying VEXAS.
3. Systemic Vasculitis / Polyarteritis Nodosa (10%): Explains mononeuritis multiplex, fever, tender nodules, and vasoplegic shock, but doesn't account for macrocytosis.
4. Myelodysplastic Syndrome (MDS) with Autoinflammation (10%): Explains macrocytic anemia and systemic inflammation, frequently overlapping with late-onset autoinflammatory phenotypes.
Recommended Prioritized Tests:
1. Targeted genetic testing for UBA1 mutations (Sanger/NGS looking at codon 41).
2. Bone marrow aspirate and biopsy (evaluating for characteristic cytoplasmic vacuolization in erythroid/myeloid precursors and MDS).
3. ANCA panel (Anti-PR3, Anti-MPO) and cryoglobulins.
4. Serum immunoglobulins and serum protein electrophoresis (SPEP).
Hello Attending Consultant here
Critique: Solid prioritization of VEXAS, but overweights isolated RP/PAN; underemphasizes MDS overlap and omits vacuoles/UBA1 as immediate anchors. Plan lacks urgency for marrow genetics and thrombosis workup depth.
Top 3 DDx:
1. VEXAS (UBA1 somatic)
2. MDS-associated VEXAS-spectrum autoinflammation
3. RP-vasculitis overlap (secondary)
5 specific points:
1. Expedite UBA1 codon 41 NGS + marrow for vacuoles now.
2. Add PET-CT for occult myeloid clone/inflammation mapping.
3. Quantify vacuoles % and dysplasia score on aspirate.
4. Full thrombophilia + JAK2/CALR given DVT/shock.
5. Hold further biologics; bridge with high-dose steroids + IL-6/IL-1 trial pending genetics.
6. Audiometry/ENT serial for chondritis progression.
7. Screen for plasma cell dyscrasia (FLC + SPEP/UPEP).
Hello, Expert Clinician here.
Best Unifying Diagnosis: VEXAS syndrome (somatic UBA1 mutation) — likely with evolving MDS.
Why it fits: This is a textbook convergence: older male, macrocytic anemia, Sweet-like neutrophilic dermatosis, relapsing polychondritis, mononeuritis multiplex, sensorineural hearing loss, venous thrombosis, and profound steroid dependence with refractoriness to methotrexate and anti-TNF agents. No single conventional rheumatologic diagnosis explains hematologic + dermatologic + cartilaginous + vascular disease simultaneously.
Key differentials:
- MDS with systemic autoinflammation: Fits marrow and inflammation, but UBA1 testing supersedes; ~1/3 of VEXAS patients have concurrent MDS.
- Isolated relapsing polychondritis: Explains chondritis/hearing loss but not macrocytosis, thrombosis, or shock — likely a downstream VEXAS phenotype.
- ANCA-negative vasculitis/PAN: Captures mononeuritis and nodules, not the cytopenias or chondritis.
- Lymphoma/occult malignancy: Fever and weight loss warrant exclusion.
Key pivot: Corticosteroid dependence + macrocytic anemia in a "seronegative RA" patient — the moment refractory rheumatologic disease met unexplained hematology, VEXAS should have been suspected.
Next move: Peripheral blood UBA1 sequencing (Sanger/NGS) plus bone marrow biopsy assessing vacuolated myeloid/erythroid precursors and MDS.
Teaching pearl: In older men with treatment-refractory "rheumatologic" disease, macrocytosis is the hematologic breadcrumb leading to VEXAS — never dismiss it as B12 deficiency alone.
Stage 2: Physical Examination & Initial Laboratory Evaluation (Timestamp: Admission / Day 1)
Physical Exam: T 38.9°C, HR 105 bpm, BP 128/72 mmHg. Patient appears chronically ill. Tender submandibular lymphadenopathy; bilateral auricle swelling/tenderness (chondritis). Diffuse violaceous plaques, pustules, and urticarial lesions across trunk, forehead, and extremities. Tenderness over wrists and PIP joints. Persistent right foot drop.
Initial Laboratory Panel:
- Hemogram: Severe Macrocytic Anemia (Hb 8.2 g/dL, MCV 106 fL), Leukopenia (WBC 3,100/µL), Thrombocytopenia (Platelets 98,000/µL) -> Pancytopenia with pronounced macrocytosis.
- Inflammatory & Biochemical Markers: ESR 78 mm/1st hr, CRP 84 mg/L, Serum Ferritin 974 ng/mL, Serum Creatinine 1.1 mg/dL, LFTs normal.
- Serum Protein Electrophoresis (SPEP): Low-level IgG kappa monoclonal protein (MGUS pattern).
- Autoimmune & Infectious Workup: ANA negative, ANCA negative, C3/C4 normal, RF 24 IU/mL, Anti-CCP negative. Blood/urine cultures negative, viral PCRs negative.
ERROR from Resident: The read operation timed out
Hello Attending Consultant here
Critique: Prior plan correctly flagged UBA1/marrow but underweighted pancytopenia+MGUS synergy; delayed PET and clone quantification risk missing MDS transformation. Escalate genetics STAT.
Top 3 DDx:
1. VEXAS (UBA1) ± MDS
2. MDS/VEXAS-spectrum with MGUS
3. RP-PAN overlap (secondary phenotype)
6 specific points:
1. STAT peripheral blood/marrow UBA1 NGS (p.Met41).
2. Marrow aspirate: quantify vacuoles, dysplasia, cytogenetics/NGS panel.
3. PET-CT for nodal/myeloid burden mapping.
4. Serum FLC + UPEP to characterize MGUS progression.
5. Hold biologics; pulse methylpred + consider ruxolitinib bridge.
6. Repeat ANCA/cryos + nerve conduction for mononeuritis extent.
7. Thrombophilia + PNH flow given prior DVT/shock.
Hello, Expert Clinician here.
Best Unifying Diagnosis: VEXAS syndrome with concurrent MDS/MDS-MPN evolution — the pancytopenia with MCV 106 fL, hyperferritinemia (974), and MGUS now strongly suggest a myeloid clone driving the autoinflammation.
Key Differentials:
- Pure VEXAS (no MDS): Fits all features, but thrombocytopenia <100k and pancytopenia at presentation favor marrow dysplasia over isolated inflammatory cytopenias.
- MDS with systemic autoinflammation (no UBA1): Overlapping phenotype; requires UBA1 testing to distinguish.
- AL Amyloidosis/Plasma cell dyscrasia: MGUS is noted, but normal creatinine and absence of neuropathy/cardiac involvement make this secondary; the MGUS is likely a "bystander" clone in the inflammatory milieu.
- Hemophagocytic lymphohistiocytosis (HLH): Ferritin is elevated but not >10,000; lacks the characteristic cytopenias/fibrinogen pattern.
Key Pivot: The transition from "seronegative RA" to pancytopenia with macrocytosis—this is the moment the rheumatologic phenotype reveals its hematologic origin.
Next Move: Immediate bone marrow biopsy with cytogenetics and UBA1 sequencing; if UBA1 negative, proceed to myeloid NGS panel.
Teaching Pearl: In VEXAS, the marrow is the "smoking gun"—vacuolated myeloid/erythroid precursors are pathognomonic, and macrocytosis often precedes the full cytopenic phenotype by months.
Stage 3: Diagnostic Biopsies & Histopathology (Timestamp: Hospital Days 3-5)
Diagnostic Interventions:
- Skin Punch Biopsy: Histopathology demonstrated a dense dermal perivascular and interstitial neutrophilic dermatosis (Sweet's-like neutrophilic infiltrate) without overt leucocytoclastic vasculitis.
- Bone Marrow Aspirate & Biopsy: Hypercellular marrow with dyserythropoiesis, 5% polyclonal plasma cells, and a striking diagnostic feature: prominent cytoplasmic vacuoles within early myeloid and erythroid precursor cells (vacuolated myeloblasts, promyelocytes, and pronormoblasts).
Hello, Chief Resident here.
Key Findings:
Pathognomonic cytoplasmic vacuoles in early myeloid and erythroid precursors, hypercellular marrow with dyserythropoiesis, and dermal Sweet-like neutrophilic dermatosis, solidifying an autoinflammatory-hematologic overlap.
Differential Diagnoses:
1. VEXAS Syndrome (95%): The constellation of macrocytic pancytopenia, chondritis, neutrophilic dermatosis, and characteristic progenitor vacuolization is nearly pathognomonic for somatic UBA1 mutations.
2. Primary MDS with non-VEXAS Autoinflammation (3%): Accounts for dysplasia and inflammation, but rarely exhibits this specific vacuole distribution.
3. Copper Deficiency / Zinc Toxicity (2%): Classic metabolic cause of marrow vacuolization and cytopenias, though unable to explain chondritis, mononeuritis, or vasoplegic shock.
Prioritized Next Steps:
1. Targeted UBA1 gene sequencing (Sanger/NGS at p.Met41) for molecular confirmation.
2. Myeloid NGS panel (TET2, DNMT3A, ASXL1) and cytogenetics on bone marrow aspirate.
3. Initiate targeted therapy: JAK inhibitor (e.g., Ruxolitinib) or hypomethylating agent (Azacitidine) to manage steroid-refractory inflammation and dysplasia.
4. Evaluate for Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) as potential definitive cure.
5. Serum copper and ceruloplasmin levels to formally exclude metabolic mimics.
Hello Attending Consultant here
Critique: Excellent anchoring on pathognomonic vacuoles; plan overweights allo-HSCT prematurely and under-specifies UBA1 variant confirmation before JAK/HMA. Copper exclusion is appropriate but low-yield here.
Top 3 DDx:
1. VEXAS (UBA1 p.Met41) ± low-grade MDS
2. MDS-autoinflammation overlap (UBA1-neg)
3. Copper deficiency mimic (excluded by phenotype)
6 specific points:
1. STAT UBA1 NGS (codon 41 hotspot) on blood/marrow.
2. Full myeloid NGS + karyotype for co-mutations/IPSS-R.
3. Quantify vacuole burden (% precursors) and dysplasia score.
4. Bridge with ruxolitinib + steroids; defer azacitidine pending genetics.
5. Serum Cu/ceruloplasmin + zinc only if UBA1 neg.
6. PET-CT + FLC to map residual MGUS/clone activity.
7. Multidisciplinary HSCT consult only if refractory post-confirmation.
Hello, Expert Clinician here.
Best Unifying Diagnosis: VEXAS syndrome — the cytoplasmic vacuoles in myeloid/erythroid precursors are pathognomonic for somatic UBA1 dysfunction; the marrow is hypercellular despite peripheral pancytopenia, indicating ineffective hematopoiesis typical of the MDS-overlap phenotype.
Top Differentials:
- Copper deficiency/Zinc toxicity: Causes vacuolated precursors and cytopenias, but lacks chondritis, mononeuritis multiplex, and neutrophilic dermatosis; obtain levels to exclude.
- Pure MDS with autoinflammation: Accounts for dysplasia and systemic symptoms, but without UBA1 mutation it does not explain the specific vacuole distribution or the peculiar steroid-dependent clinical phenotype.
- VEXAS-MDS overlap: Most likely; ~30% of VEXAS patients meet MDS criteria, and the 5% plasma cells represent a benign MGUS clone rather than marrow failure driver.
Key Pivot: The marrow vacuolization is the "smoking gun" that converts a clinical suspicion into a near-certain diagnosis; it precedes and predicts UBA1 mutation confirmation.
Next Move: Peripheral blood or marrow UBA1 sequencing (Sanger/NGS) targeting p.Met41; simultaneously send for myeloid NGS panel to assess clonal architecture and prognosis.
Teaching Pearl: In VEXAS, marrow vacuoles are highly sensitive and specific—if you see them in an older male with macrocytosis and autoinflammation, you have found the disease; genetic confirmation is academic rather than necessary for initiating therapy.
Stage 4: Targeted Molecular & Genetic Confirmation (Timestamp: Hospital Day 7)
Given the combination of refractory autoinflammation, neutrophilic dermatosis, relapsing chondritis, macrocytic pancytopenia, DVT, and characteristic marrow myeloid/erythroid vacuoles, specialized molecular testing was performed:
- Targeted Genetic Testing: Somatic UBA1 Gene Mutation Analysis (PCR and targeted NGS for the UBA1 gene on the X-chromosome).
- Molecular Result: Identified a somatic UBA1 mutation (p.Met41 / Met41Val substitution) in hematopoietic precursor cells, confirming the diagnosis.
Hello, Chief Resident here.
Updated Key Findings:
Molecular confirmation of a somatic UBA1 mutation (p.Met41Val), definitively establishing the diagnosis of VEXAS syndrome underlying the patient's multi-system autoinflammation, macrocytic pancytopenia, marrow vacuolization, and thrombotic events.
Diagnosis:
1. VEXAS Syndrome (100%): Formally confirmed by UBA1 p.Met41Val mutation, fully accounting for the DMARD-refractory arthritis, relapsing chondritis, Sweet-like dermatosis, mononeuritis multiplex, cytopenias, and vasoplegic shock.
Prioritized Management & Next Steps:
1. Targeted Immunomodulation: Initiate a JAK inhibitor (e.g., Ruxolitinib) or hypomethylating agent (e.g., Azacitidine) to control severe autoinflammation and taper steroids.
2. Curative Evaluation: Refer to a transplant center for early evaluation of Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT), the only definitive cure.
3. Clonal Risk Stratification: Complete myeloid NGS panel (e.g., TET2, DNMT3A) and cytogenetics to stratify underlying MDS risk via IPSS-R.
4. Anticoagulation Strategy: Optimize long-term therapeutic anticoagulation given high recurrent thrombotic risk.
5. Supportive Care: Provide G-CSF, blood product support as needed, and monitor for opportunistic infections during immunosuppression.
Hello Attending Consultant here
Critique: Plan correctly pivots to JAK/HMA and HSCT but overcalls "100%" without co-mutation risk; delays full clonal mapping and under-specifies steroid-sparing bridge plus thrombosis prophylaxis intensity.
Top 3 DDx:
1. VEXAS (UBA1 p.Met41Val) with MDS overlap
2. VEXAS-MDS/MPN continuum
3. Secondary RP/vasculitis phenotype (resolved)
6 specific points:
1. Complete myeloid NGS + karyotype/IPSS-R STAT for co-mutations.
2. Start ruxolitinib 10-15 mg BID + rapid steroid taper.
3. Add azacitidine if dysplasia progresses or cytopenias worsen.
4. Lifelong anticoagulation (DOAC preferred) given VEXAS thrombosis risk.
5. Early allo-HSCT referral; bridge with supportive G-CSF/transfusions.
6. Serial ferritin/CRP + PET for response; screen infections pre-HSCT.
7. ENT/neuro follow-up for chondritis/mononeuritis sequelae.
Hello, Expert Clinician here.
Definitive Diagnosis: VEXAS syndrome — the somatic UBA1 p.Met41Val mutation provides the molecular "smoking gun," unifying the autoinflammatory, hematologic, and thrombotic phenotypes into a single X-linked somatic disorder.
Key Differentials Resolved:
- MDS overlap: High probability; requires immediate IPSS-R stratification and myeloid NGS to define co-mutational landscape and progression risk.
- Secondary amyloidosis: Chronic inflammation and MGUS warrant exclusion via serum free light chains and tissue biopsy if organ dysfunction emerges.
- Opportunistic infection: Must be excluded before escalating immunosuppression (JAK inhibition or azacitidine).
Key Pivot: The identification of p.Met41Val transforms management from empiric anti-cytokine therapy to targeted JAK inhibition and definitive HSCT evaluation; it also predicts potential refractoriness to IL-6 blockade alone.
Next Move: Initiate ruxolitinib to enable steroid taper while simultaneously obtaining full myeloid NGS panel, karyotype, and early referral to transplant for allo-HSCT evaluation.
Teaching Pearl: UBA1 mutations are restricted to hematopoietic precursors—germline testing is negative, underscoring that VEXAS is an acquired somatic disorder of aging, not an inherited germline immunodeficiency.
Stage 5: Final Unifying Diagnosis & Clinical Course (Timestamp: Follow-up & Discharge)
Final Unifying Diagnosis: VEXAS Syndrome (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic UBA1 mutation) presenting with neutrophilic dermatosis, relapsing polychondritis, macrocytic pancytopenia, DVT, and vasoplegic shock.
Treatment Plan: Initiation of targeted JAK inhibitor therapy with Ruxolitinib (10mg BD) to suppress monocyte-driven autoinflammation, rapid weaning of high-dose corticosteroids, supportive blood transfusions, and evaluation for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).
Outcome: Resolution of fever and cutaneous neutrophilic plaques, stabilization of hemogram, successful reduction of steroid burden, and referral to a bone marrow transplant center for curative HSCT.
Hello, Chief Resident here.
Updated Key Findings:
Definitive molecular confirmation of VEXAS syndrome (UBA1 p.Met41Val mutation) in an older male presenting with macrocytic pancytopenia, characteristic progenitor vacuolization, chondritis, Sweet-like dermatosis, and vasoplegic shock, now clinically responding to targeted JAK inhibition (Ruxolitinib).
Probability-Based Diagnoses:
1. VEXAS Syndrome without high-risk MDS (80%): Confirmed by UBA1 p.Met41Val mutation, rapid clinical and biomarker response to Ruxolitinib and steroid tapering.
2. VEXAS Syndrome with MDS Overlap (20%): Supported by dyserythropoiesis and persistent cytopenias; pending full myeloid gene panel results to define clonal burden.
Prioritized Management & Next Steps:
1. Complete myeloid NGS panel and cytogenetics on bone marrow to calculate IPSS-R score and stratify MDS risk.
2. Allo-HSCT evaluation: Initiate HLA typing and donor search for definitive curative therapy.
3. Optimized immunosuppressive monitoring: Serial CRP, ferritin, CBC, and vigilant infection surveillance while on Ruxolitinib.
4. Long-term therapeutic anticoagulation: Continue DOAC therapy due to the inherently elevated thrombotic risk in VEXAS.
5. Serial ENT/Audiology surveillance: Track chondritis stability and prevent airway compromise.
Hello Attending Consultant here
Critique: Plan appropriately locks in confirmed VEXAS and ruxolitinib response but under-specifies co-mutation-driven MDS risk stratification and infection prophylaxis intensity pre-HSCT; anticoagulation duration needs explicit lifelong framing.
Top 3 DDx:
1. VEXAS (UBA1 p.Met41Val) ± low-risk MDS
2. VEXAS-MDS continuum (co-mutated)
3. Residual secondary RP phenotype (resolved)
6 specific points:
1. Expedite full myeloid NGS/karyotype for IPSS-R and co-mutations (TET2/DNMT3A).
2. Continue ruxolitinib 10 mg BID; taper steroids to physiologic within 4 weeks.
3. Initiate HLA typing/donor search; bridge with G-CSF if ANC drops.
4. Lifelong DOAC; add ASA if arterial events emerge.
5. PCP/antifungal prophylaxis + serial ferritin/CRP q2 weeks.
6. Baseline PFTs/echo + PET pre-HSCT; ENT for residual chondritis.
7. Monitor MGUS FLC for clonal evolution.
Hello, Expert Clinician here.
Best Unifying Diagnosis: VEXAS syndrome (somatic UBA1 p.Met41Val), presenting as a steroid-dependent "seronegative RA" with evolution to life-threatening multisystem autoinflammation, now responding to ruxolitinib.
Key Differentials Resolved:
- MDS overlap: Hypercellular marrow with dyserythropoiesis suggests concurrent myelodysplasia; ruxolitinib controls inflammation but does not modify the myeloid clone—azacitidine may be required if cytopenias progress.
- Allo-HSCT candidacy: Only curative option; evaluation is urgent given the risk of MDS progression or refractory shock. Age alone (72) is not an absolute contraindication if comorbidity index is favorable.
- Infectious mimics: Ruxolitinib increases risk of TB and viral reactivation; ensure negative IGRA and HBV/HCV serologies before escalation.
Key Pivot: Recognition that the "refractory RA" was a phenocopy; the macrocytic pancytopenia and vacuoles should have triggered UBA1 testing years earlier, potentially avoiding the vasoplegic shock and multiple ICU admissions.
Next Move: Complete pre-transplant workup (myeloid NGS panel for prognostication, HLA typing, comorbidity index) while bridging with ruxolitinib; consider azacitidine if del(5q) or TP53 mutations are identified.
Teaching Pearl: VEXAS is the prototype of "hemato-inflammation"—a somatic mutation in hematopoietic precursors that hijacks the innate immune system, teaching us that some "autoimmune" diseases are actually acquired genetic disorders of aging.